N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020)
Due to the urgency of the COVID-19 crisis, the testing of pharmaceuticals that had already cleared safety and production hurdles began within the first month of the outbreak.
Observational and compassionate-use studies of repurposed drugs proliferated rapidly, as did clinical trials. The corticosteroid dexamethasone was shown, in the large-scale UK RECOVERY trial, to reduce 28-day mortality by as much as a third in patients hospitalized with COVID-19 and receiving either mechanical ventilation or oxygen alone, compared with the mortality of those receiving the usual care.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carvalho, T. Dexamethasone reduces mortality. Nat Med 26, 1806 (2020). https://doi.org/10.1038/s41591-020-01158-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-01158-9